{"product_id":"teriparatide-10mg-vial","title":"Teriparatide 10mg vial","description":"\u003cp data-start=\"110\" data-end=\"431\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                          \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"110\" data-end=\"431\"\u003e\u003cstrong data-start=\"110\" data-end=\"126\"\u003eTeriparatide\u003c\/strong\u003e is a \u003cstrong data-start=\"132\" data-end=\"182\"\u003erecombinant human parathyroid hormone fragment\u003c\/strong\u003e comprising the \u003cstrong data-start=\"198\" data-end=\"245\"\u003eN-terminal 34 amino acids of endogenous PTH\u003c\/strong\u003e (PTH 1–34). It is administered as a \u003cstrong data-start=\"282\" data-end=\"319\"\u003eonce-daily subcutaneous injection\u003c\/strong\u003e and is the prototypical \u003cstrong data-start=\"344\" data-end=\"392\"\u003eanabolic (bone-forming) osteoporosis therapy\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"433\" data-end=\"670\"\u003e\u003cstrong data-start=\"433\" data-end=\"454\"\u003eRegulatory status\u003c\/strong\u003e\u003cbr\u003eTeriparatide is an approved medicine in major markets (e.g., \u003cstrong data-start=\"516\" data-end=\"526\"\u003eForteo\u003c\/strong\u003e in the US; \u003cstrong data-start=\"538\" data-end=\"549\"\u003eForsteo\u003c\/strong\u003e in Europe), with multiple approved generics\/biosimilars depending on jurisdiction. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"672\" data-end=\"675\"\u003e\n\u003ch2 data-start=\"677\" data-end=\"717\"\u003e2) Clinical indications (label-based)\u003c\/h2\u003e\n\u003cp data-start=\"718\" data-end=\"831\"\u003eFrom US and EU labeling, teriparatide is used for \u003cstrong data-start=\"768\" data-end=\"819\"\u003eosteoporosis in adults at high risk of fracture\u003c\/strong\u003e, including:\u003c\/p\u003e\n\u003cul data-start=\"832\" data-end=\"1259\"\u003e\n\u003cli data-start=\"832\" data-end=\"991\"\u003e\n\u003cp data-start=\"834\" data-end=\"991\"\u003e\u003cstrong data-start=\"834\" data-end=\"876\"\u003ePostmenopausal women with osteoporosis\u003c\/strong\u003e at high risk for fracture (reduces vertebral and non-vertebral fractures). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"992\" data-end=\"1131\"\u003e\n\u003cp data-start=\"994\" data-end=\"1131\"\u003e\u003cstrong data-start=\"994\" data-end=\"1042\"\u003eMen with primary or hypogonadal osteoporosis\u003c\/strong\u003e at high risk for fracture (increases bone mass). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"1132\" data-end=\"1259\"\u003e\n\u003cp data-start=\"1134\" data-end=\"1259\"\u003e\u003cstrong data-start=\"1134\" data-end=\"1192\"\u003eMen and women with glucocorticoid-induced osteoporosis\u003c\/strong\u003e at high risk for fracture. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"1261\" data-end=\"1455\"\u003e(Exact wording varies slightly by product\/region, but the “high fracture risk \/ failed or intolerant to other therapy” framing is consistent across labels.) \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"1457\" data-end=\"1460\"\u003e\n\u003ch2 data-start=\"1462\" data-end=\"1497\"\u003e3) Molecular mechanism of action\u003c\/h2\u003e\n\u003ch3 data-start=\"1499\" data-end=\"1532\"\u003e3.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cp data-start=\"1533\" data-end=\"1721\"\u003eTeriparatide is an agonist of the \u003cstrong data-start=\"1567\" data-end=\"1592\"\u003ePTH1 receptor (PTH1R)\u003c\/strong\u003e (a class B GPCR) expressed on \u003cstrong data-start=\"1623\" data-end=\"1651\"\u003eosteoblast lineage cells\u003c\/strong\u003e (and renal tubular cells). Its biology is defined by a key principle:\u003c\/p\u003e\n\u003cblockquote data-start=\"1723\" data-end=\"1840\"\u003e\n\u003cp data-start=\"1725\" data-end=\"1840\"\u003e\u003cstrong data-start=\"1725\" data-end=\"1741\"\u003eIntermittent\u003c\/strong\u003e PTH1R stimulation → \u003cstrong data-start=\"1762\" data-end=\"1784\"\u003enet bone formation\u003c\/strong\u003e\u003cbr data-start=\"1784\" data-end=\"1787\"\u003e\u003cstrong data-start=\"1789\" data-end=\"1803\"\u003eContinuous\u003c\/strong\u003e PTH excess → \u003cstrong data-start=\"1817\" data-end=\"1840\"\u003enet bone resorption\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003cp data-start=\"1842\" data-end=\"1973\"\u003eThis “intermittency effect” is the central mechanistic reason daily teriparatide is anabolic. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"1975\" data-end=\"2038\"\u003e3.2 Cellular and tissue-level effects (how bone mass rises)\u003c\/h3\u003e\n\u003cp data-start=\"2039\" data-end=\"2160\"\u003eIntermittent teriparatide increases bone formation largely by increasing the \u003cstrong data-start=\"2116\" data-end=\"2154\"\u003enumber and activity of osteoblasts\u003c\/strong\u003e, via:\u003c\/p\u003e\n\u003cul data-start=\"2161\" data-end=\"2368\"\u003e\n\u003cli data-start=\"2161\" data-end=\"2198\"\u003e\n\u003cp data-start=\"2163\" data-end=\"2198\"\u003eactivation of existing osteoblasts,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2199\" data-end=\"2258\"\u003e\n\u003cp data-start=\"2201\" data-end=\"2258\"\u003epromotion of osteoblast differentiation from progenitors,\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2259\" data-end=\"2310\"\u003e\n\u003cp data-start=\"2261\" data-end=\"2310\"\u003ereduced osteoblast apoptosis (context-dependent),\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2311\" data-end=\"2368\"\u003e\n\u003cp data-start=\"2313\" data-end=\"2368\"\u003estimulation of remodeling and modeling-based formation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"2370\" data-end=\"2549\"\u003eA characteristic biomarker pattern is the \u003cstrong data-start=\"2412\" data-end=\"2433\"\u003e“anabolic window”\u003c\/strong\u003e: \u003cstrong data-start=\"2435\" data-end=\"2472\"\u003ebone formation markers rise first\u003c\/strong\u003e, followed later by resorption markers. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"2551\" data-end=\"2592\"\u003e3.3 Downstream signaling (high-level)\u003c\/h3\u003e\n\u003cp data-start=\"2593\" data-end=\"2901\"\u003ePTH1R signaling involves \u003cstrong data-start=\"2618\" data-end=\"2630\"\u003ecAMP\/PKA\u003c\/strong\u003e and related pathways in bone cells, which shifts transcriptional programs toward osteoblast function and alters osteoblast–osteoclast coupling (e.g., via RANKL\/OPG dynamics), producing net anabolic effects when dosed intermittently. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"2903\" data-end=\"2906\"\u003e\n\u003ch2 data-start=\"2908\" data-end=\"2949\"\u003e4) Pharmacokinetics and administration\u003c\/h2\u003e\n\u003cp data-start=\"2950\" data-end=\"3374\"\u003e\u003cstrong data-start=\"2950\" data-end=\"2960\"\u003eRoute:\u003c\/strong\u003e Subcutaneous injection, \u003cstrong data-start=\"2985\" data-end=\"3005\"\u003e20 μg once daily\u003c\/strong\u003e is the canonical dose for originator products. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003cbr data-start=\"3090\" data-end=\"3093\"\u003eAs a peptide hormone fragment, teriparatide has \u003cstrong data-start=\"3141\" data-end=\"3169\"\u003erapid systemic clearance\u003c\/strong\u003e relative to monoclonal antibodies and acts through \u003cstrong data-start=\"3221\" data-end=\"3249\"\u003epulsatile daily exposure\u003c\/strong\u003e, consistent with its anabolic mechanism (the “intermittent vs continuous” paradigm). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"3376\" data-end=\"3379\"\u003e\n\u003ch2 data-start=\"3381\" data-end=\"3428\"\u003e5) Clinical efficacy (what it reliably does)\u003c\/h2\u003e\n\u003ch3 data-start=\"3430\" data-end=\"3459\"\u003e5.1 Fracture risk and BMD\u003c\/h3\u003e\n\u003cp data-start=\"3460\" data-end=\"3632\"\u003eIn postmenopausal osteoporosis, teriparatide \u003cstrong data-start=\"3505\" data-end=\"3554\"\u003ereduces vertebral and non-vertebral fractures\u003c\/strong\u003e and increases BMD (especially spine). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"3634\" data-end=\"3677\"\u003e5.2 Glucocorticoid-induced osteoporosis\u003c\/h3\u003e\n\u003cp data-start=\"3678\" data-end=\"3977\"\u003eTeriparatide is used in adults with osteoporosis associated with sustained systemic glucocorticoids at high fracture risk and increases bone mass; it is often considered when fracture risk is very high or antiresorptives are insufficient\/tolerability-limited. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003ch3 data-start=\"3979\" data-end=\"4013\"\u003e5.3 Practical place in therapy\u003c\/h3\u003e\n\u003cp data-start=\"4014\" data-end=\"4475\"\u003eGuidelines vary, but teriparatide is classically positioned for \u003cstrong data-start=\"4078\" data-end=\"4105\"\u003every high fracture risk\u003c\/strong\u003e (multiple fractures, very low T-score, or failure\/intolerance of other therapies), and commonly followed by an \u003cstrong data-start=\"4217\" data-end=\"4259\"\u003eantiresorptive “consolidation” therapy\u003c\/strong\u003eto maintain gains (because anabolic gains can regress after stopping without follow-on treatment). (This sequencing approach is widely taught in osteoporosis practice; check your local guideline for exact phrasing.)\u003c\/p\u003e\n\u003chr data-start=\"4477\" data-end=\"4480\"\u003e\n\u003ch2 data-start=\"4482\" data-end=\"4548\"\u003e6) Safety and tolerability (label-informed, mechanism-informed)\u003c\/h2\u003e\n\u003ch3 data-start=\"4550\" data-end=\"4580\"\u003e6.1 Common adverse effects\u003c\/h3\u003e\n\u003cp data-start=\"4581\" data-end=\"4613\"\u003eTypical adverse effects include:\u003c\/p\u003e\n\u003cul data-start=\"4614\" data-end=\"4849\"\u003e\n\u003cli data-start=\"4614\" data-end=\"4655\"\u003e\n\u003cp data-start=\"4616\" data-end=\"4655\"\u003e\u003cstrong data-start=\"4616\" data-end=\"4626\"\u003enausea\u003c\/strong\u003e, \u003cstrong data-start=\"4628\" data-end=\"4640\"\u003eheadache\u003c\/strong\u003e, \u003cstrong data-start=\"4642\" data-end=\"4655\"\u003edizziness\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4656\" data-end=\"4722\"\u003e\n\u003cp data-start=\"4658\" data-end=\"4722\"\u003e\u003cstrong data-start=\"4658\" data-end=\"4685\"\u003eorthostatic hypotension\u003c\/strong\u003e (particularly early after injection)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4723\" data-end=\"4739\"\u003e\n\u003cp data-start=\"4725\" data-end=\"4739\"\u003e\u003cstrong data-start=\"4725\" data-end=\"4739\"\u003eleg cramps\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"4740\" data-end=\"4849\"\u003e\n\u003cp data-start=\"4742\" data-end=\"4849\"\u003e\u003cstrong data-start=\"4742\" data-end=\"4759\"\u003ehypercalcemia\u003c\/strong\u003e (usually mild\/transient; monitor if risk factors) \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4851\" data-end=\"4909\"\u003e6.2 Osteosarcoma signal: what changed and what remains\u003c\/h3\u003e\n\u003cul data-start=\"4910\" data-end=\"5448\"\u003e\n\u003cli data-start=\"4910\" data-end=\"5098\"\u003e\n\u003cp data-start=\"4912\" data-end=\"5098\"\u003eThe US boxed warning about osteosarcoma was \u003cstrong data-start=\"4956\" data-end=\"4967\"\u003eremoved\u003c\/strong\u003e (label change noted in 2020), reflecting postmarketing surveillance and risk evaluation. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5099\" data-end=\"5448\"\u003e\n\u003cp data-start=\"5101\" data-end=\"5448\"\u003eHowever, labeling still includes discussion\/precautionary language around osteosarcoma risk and recommends avoiding use in patients with conditions that increase baseline osteosarcoma risk (e.g., Paget disease of bone, unexplained elevated alkaline phosphatase, prior skeletal radiation, bone metastases). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"5450\" data-end=\"5470\"\u003e6.3 Use duration\u003c\/h3\u003e\n\u003cp data-start=\"5471\" data-end=\"5773\"\u003eHistorically, teriparatide had a \u003cstrong data-start=\"5504\" data-end=\"5531\"\u003e24-month lifetime limit\u003c\/strong\u003e in many settings; labeling language evolved after the boxed warning removal, but long-term use beyond 2 years remains a specialist decision balancing risk\/benefit and the limited long-duration dataset. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"5775\" data-end=\"5778\"\u003e\n\u003ch2 data-start=\"5780\" data-end=\"5806\"\u003e7) Regulatory landscape\u003c\/h2\u003e\n\u003cul data-start=\"5807\" data-end=\"6133\"\u003e\n\u003cli data-start=\"5807\" data-end=\"6001\"\u003e\n\u003cp data-start=\"5809\" data-end=\"6001\"\u003e\u003cstrong data-start=\"5809\" data-end=\"5816\"\u003eUS:\u003c\/strong\u003e Forteo label updated; boxed warning removed; teriparatide injections (originator and generics) have current prescribing information available. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"6002\" data-end=\"6133\"\u003e\n\u003cp data-start=\"6004\" data-end=\"6133\"\u003e\u003cstrong data-start=\"6004\" data-end=\"6011\"\u003eEU:\u003c\/strong\u003e Forsteo remains an authorized product with an EMA EPAR and product information. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6135\" data-end=\"6138\"\u003e\n\u003ch2 data-start=\"6140\" data-end=\"6184\"\u003e8) Comparative positioning (quick matrix)\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6186\" data-end=\"6779\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6186\" data-end=\"6277\"\u003e\n\u003ctr data-start=\"6186\" data-end=\"6277\"\u003e\n\u003cth data-start=\"6186\" data-end=\"6196\" data-col-size=\"sm\"\u003eFeature\u003c\/th\u003e\n\u003cth data-start=\"6196\" data-end=\"6222\" data-col-size=\"md\"\u003eTeriparatide (PTH 1–34)\u003c\/th\u003e\n\u003cth data-start=\"6222\" data-end=\"6277\" data-col-size=\"md\"\u003eTypical antiresorptives (bisphosphonates\/denosumab)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6292\" data-end=\"6779\"\u003e\n\u003ctr data-start=\"6292\" data-end=\"6385\"\u003e\n\u003ctd data-start=\"6292\" data-end=\"6309\" data-col-size=\"sm\"\u003ePrimary effect\u003c\/td\u003e\n\u003ctd data-start=\"6309\" data-end=\"6343\" data-col-size=\"md\"\u003e\n\u003cstrong data-start=\"6311\" data-end=\"6323\"\u003eAnabolic\u003c\/strong\u003e (↑ bone formation)\u003c\/td\u003e\n\u003ctd data-start=\"6343\" data-end=\"6385\" data-col-size=\"md\"\u003e\n\u003cstrong data-start=\"6345\" data-end=\"6363\"\u003eAntiresorptive\u003c\/strong\u003e (↓ bone resorption)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6386\" data-end=\"6525\"\u003e\n\u003ctd data-start=\"6386\" data-end=\"6399\" data-col-size=\"sm\"\u003eBiomarkers\u003c\/td\u003e\n\u003ctd data-start=\"6399\" data-end=\"6490\" data-col-size=\"md\"\u003eformation markers rise early (“anabolic window”) \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"6490\" data-end=\"6525\" data-col-size=\"md\"\u003eresorption markers fall quickly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6526\" data-end=\"6671\"\u003e\n\u003ctd data-start=\"6526\" data-end=\"6537\" data-col-size=\"sm\"\u003eBest fit\u003c\/td\u003e\n\u003ctd data-start=\"6537\" data-end=\"6610\" data-col-size=\"md\"\u003every high fracture risk; multiple fractures; severe spine osteoporosis\u003c\/td\u003e\n\u003ctd data-start=\"6610\" data-end=\"6671\" data-col-size=\"md\"\u003ebroad osteoporosis populations; maintenance\/consolidation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6672\" data-end=\"6779\"\u003e\n\u003ctd data-start=\"6672\" data-end=\"6685\" data-col-size=\"sm\"\u003eSequencing\u003c\/td\u003e\n\u003ctd data-start=\"6685\" data-end=\"6738\" data-col-size=\"md\"\u003eoften followed by antiresorptive to maintain gains\u003c\/td\u003e\n\u003ctd data-start=\"6738\" data-end=\"6779\" data-col-size=\"md\"\u003ecan precede anabolic in many pathways\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6781\" data-end=\"6784\"\u003e\n\u003ch2 data-start=\"6786\" data-end=\"6840\"\u003e9) Future directions and clinical science questions\u003c\/h2\u003e\n\u003cp data-start=\"6841\" data-end=\"6945\"\u003eHigh-value ongoing questions in the field are less about “does it work” and more about \u003cstrong data-start=\"6928\" data-end=\"6944\"\u003eoptimization\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-start=\"6946\" data-end=\"7278\"\u003e\n\u003cli data-start=\"6946\" data-end=\"7039\"\u003e\n\u003cp data-start=\"6948\" data-end=\"7039\"\u003e\u003cstrong data-start=\"6948\" data-end=\"6971\"\u003eSequence strategies\u003c\/strong\u003e (anabolic first vs antiresorptive first in very high-risk patients)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7040\" data-end=\"7113\"\u003e\n\u003cp data-start=\"7042\" data-end=\"7113\"\u003e\u003cstrong data-start=\"7042\" data-end=\"7067\"\u003ePersonalized duration\u003c\/strong\u003e and monitoring strategies after label changes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7114\" data-end=\"7192\"\u003e\n\u003cp data-start=\"7116\" data-end=\"7192\"\u003e\u003cstrong data-start=\"7116\" data-end=\"7152\"\u003eCombination\/transition protocols\u003c\/strong\u003e to preserve BMD and reduce rebound risk\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7193\" data-end=\"7278\"\u003e\n\u003cp data-start=\"7195\" data-end=\"7278\"\u003eBetter \u003cstrong data-start=\"7202\" data-end=\"7234\"\u003efracture-risk stratification\u003c\/strong\u003e to target anabolic therapy cost-effectively\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7280\" data-end=\"7283\"\u003e\n\u003ch2 data-start=\"7285\" data-end=\"7327\"\u003eSelected references (most load-bearing)\u003c\/h2\u003e\n\u003cul data-start=\"7328\" data-end=\"7818\"\u003e\n\u003cli data-start=\"7328\" data-end=\"7427\"\u003e\n\u003cp data-start=\"7330\" data-end=\"7427\"\u003eCurrent US Forteo prescribing information (2024 label): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7428\" data-end=\"7511\"\u003e\n\u003cp data-start=\"7430\" data-end=\"7511\"\u003eEMA Forsteo product information (SmPC): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7512\" data-end=\"7633\"\u003e\n\u003cp data-start=\"7514\" data-end=\"7633\"\u003e“Intermittent vs continuous PTH” principle and clinical pharmacology summary: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7634\" data-end=\"7727\"\u003e\n\u003cp data-start=\"7636\" data-end=\"7727\"\u003eOsteosarcoma warning history and evidence review: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7728\" data-end=\"7818\"\u003e\n\u003cp data-start=\"7730\" data-end=\"7818\"\u003eBiomarker pattern (formation then resorption)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684838699346,"sku":null,"price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/Teriparatide_10mg.png?v=1770834790","url":"https:\/\/sciencepeptideslab.com\/products\/teriparatide-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}